Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Amphivena Therapeutics Inc.
DescriptionTetravalent, bispecific compound targeting CD3 receptor and CD33 antigen
Molecular Target CD3 ; CD33
Mechanism of ActionAntibody
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentIND
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today